Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewLenalidomide for the treatment of B-cell lymphoma.Expanding role of lenalidomide in hematologic malignanciesLenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis.New therapies in non-Hodgkin lymphoma.Ofatumumab in the treatment of non-Hodgkin's lymphomas.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia.Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.A Phase I Study of Ibrutinib in Combination with R-ICE in Patients with Relapsed or Primary Refractory DLBCL.Lenalidomide Maintenance after R-CHOP Therapy in Diffuse Large B-Cell Lymphoma: Can It Be a Standard of Care?
P2860
Q27304386-C1363F44-1BC4-4771-94E3-20559AA22890Q30249007-BB71C95B-90A8-44D8-AD9F-362572822F3FQ35592305-7049C512-27E0-4C43-8218-2715761FDFB4Q36046230-F1C18DE3-504F-4961-86FD-AD1359ABE113Q38315779-EB95266E-F9C9-4A69-BBFB-AD570622F1A5Q38516077-44FB41A4-DFAC-431A-BAC5-FA42BE16477DQ38594364-B6FFA608-98C5-40F1-AB1A-6D1AF0C043F2Q38728592-29E6757B-DA05-4196-A46D-8FCD1F439227Q40022297-CB3CBA2A-E3B1-4188-A531-AC07EA8A480BQ40473999-09FD29A1-A538-4E94-92F5-9AE3CDB54057Q42087653-396818CD-30BC-4ADD-A7C9-FFE0431D0D43Q48131462-616E113A-97C4-43EB-84F0-7A3CAD4771B3Q50048621-077603CB-FABF-4AF8-B18C-C9F9A8C71AF1
P2860
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@ast
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@en
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@nl
type
label
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@ast
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@en
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@nl
prefLabel
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@ast
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@en
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@nl
P2093
P2860
P356
P1476
Addition of lenalidomide to ri ...... diffuse large B-cell lymphoma
@en
P2093
Andrew L Pecora
Anne W Beaven
Anthony R Mato
Carolanne Carini
Coleen Bejot
Ewelina A Protomastro
Gabriella Gadaleta
Judith Smith
Kar F Chow
P2860
P356
10.1111/BJH.12846
P407
P577
2014-03-25T00:00:00Z